Last reviewed · How we verify

Seretide Accuhaler® 500/50 µg/actuation

Chiesi Farmaceutici S.p.A. · Phase 3 active Small molecule

Seretide Accuhaler® 500/50 µg/actuation is a Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameSeretide Accuhaler® 500/50 µg/actuation
SponsorChiesi Farmaceutici S.p.A.
Drug classCombination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA)
TargetBeta-2 adrenergic receptor; glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Salmeterol acts as a bronchodilator by stimulating beta-2 adrenergic receptors on airway smooth muscle, while fluticasone propionate is a corticosteroid that suppresses airway inflammation, mucus production, and airway hyperresponsiveness. Together, these agents provide both acute symptom relief and long-term control of asthma and COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Seretide Accuhaler® 500/50 µg/actuation

What is Seretide Accuhaler® 500/50 µg/actuation?

Seretide Accuhaler® 500/50 µg/actuation is a Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) drug developed by Chiesi Farmaceutici S.p.A., indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Seretide Accuhaler® 500/50 µg/actuation work?

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

What is Seretide Accuhaler® 500/50 µg/actuation used for?

Seretide Accuhaler® 500/50 µg/actuation is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Seretide Accuhaler® 500/50 µg/actuation?

Seretide Accuhaler® 500/50 µg/actuation is developed by Chiesi Farmaceutici S.p.A. (see full Chiesi Farmaceutici S.p.A. pipeline at /company/chiesi-farmaceutici-s-p-a).

What drug class is Seretide Accuhaler® 500/50 µg/actuation in?

Seretide Accuhaler® 500/50 µg/actuation belongs to the Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) class. See all Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) drugs at /class/combination-inhaled-corticosteroid-long-acting-beta-2-agonist-ics-laba.

What development phase is Seretide Accuhaler® 500/50 µg/actuation in?

Seretide Accuhaler® 500/50 µg/actuation is in Phase 3.

What are the side effects of Seretide Accuhaler® 500/50 µg/actuation?

Common side effects of Seretide Accuhaler® 500/50 µg/actuation include Tremor, Headache, Palpitations, Oral candidiasis, Throat irritation, Muscle cramps.

What does Seretide Accuhaler® 500/50 µg/actuation target?

Seretide Accuhaler® 500/50 µg/actuation targets Beta-2 adrenergic receptor; glucocorticoid receptor and is a Combination inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA).

Related